What Angistad Treats: Main Uses and Benefits

Angistad (Isosorbide Mononitrate) is generally applied for chronic, long-term management in cardiology, and is relevant for easing the overall symptom load and supporting symptom management in situations where patients experience cardiac stress. The medication is primarily utilized for conditions involving recurring symptomatic chest pain such as Stable Angina Pectoris and symptoms linked to organ-specific functional stress associated with coronary artery disease.

Its primary therapeutic relevance involves supporting the management of symptoms related to episodic or fluctuating manifestations. This helps address symptoms that create noticeable physiological strain and interfere with daily comfort. When used as part of supportive care, the treatment supports the patient during episodes of heightened discomfort.

The treatment is commonly used to help with managing symptom intensity and recurrence, which contributes to improved comfort during periods of heightened symptoms. When applied appropriately in conditions marked by increased physiological stress, this use assists with maintaining functional stability and general well-being during symptomatic phases.

“This medication is applied across domains where additional symptomatic support is needed to help patients cope more steadily with difficult episodes.”

---

Quick Fact: Relief for Chest Discomfort

Property	Description
Primary Indication	Stable Angina Pectoris
Focus of Use	Symptom Management
Core Benefit	Easing overall symptom burden
Typical Application	Chronic, long-term supportive care

Regulatory References

1. NIH DailyMed label for Isosorbide Mononitrate

Who Can and Cannot Use Angistad?

Angistad (Isosorbide Mononitrate) eligibility is defined by regulatory authorities based on specific clinical and physiological constraints. The medicine is primarily intended for adults who are not subject to the absolute prohibitions listed below.

---

Absolute Prohibitions (Contraindications)

Official labeling strictly prohibits the use of Angistad in patients with certain conditions or who are taking specific medications:

• Hypersensitivity: Known allergy to isosorbide mononitrate or any other nitrates.
• Concurrent Drug Use: Must not be used by patients taking Phosphodiesterase Type-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) or Soluble Guanylate Cyclase (sGC) stimulators (e.g., riociguat).
• Severe Acute Conditions: Prohibited in patients with acute circulatory failure (shock/collapse), cardiogenic shock, marked hypotension (systolic BP le 90 mmHg), or marked anaemia.

---

Population-Specific Restrictions

Population	Regulatory Status
Children/Adolescents	Not Recommended. Safety and efficacy are not established due to lack of data.
Older Adults (Geriatric)	Use is permitted, but caution is advised due to increased susceptibility to hypotensive effects.
Pregnancy/Lactation	Restricted. Use is permitted only if the benefit outweighs the unknown hazard due to limited human safety data.
Organ Impairment	Caution is required in severe renal or hepatic impairment, although no routine dose adjustment is specified in the label.

Interactions with other medicines and products

Angistad (Isosorbide Mononitrate) interacts with specific medications and substances, primarily due to additive effects on blood pressure. These interactions are categorized by their severity and the constraints they impose on concomitant use, as detailed in official regulatory documents.

---

Contraindicated Combinations

Co-administration of Angistad is contraindicated with the following agents due to the potential for severe, life-threatening hypotension, syncope, or myocardial ischemia:

• Phosphodiesterase 5 (PDE5) inhibitors, including sildenafil, tadalafil, and vardenafil, which are used for erectile dysfunction or pulmonary hypertension.
• Soluble Guanylate Cyclase (sGC) stimulators, such as riociguat.

Combinations Requiring Caution

Concomitant use with the following agents may potentiate the blood pressure-lowering effect of Angistad, requiring medical supervision:

• Antihypertensive agents (e.g., beta-blockers, calcium channel antagonists).
• Other vasodilators (blood vessel dilating agents).
• Neuroleptics and Tricyclic antidepressants.
• Alcohol.

Other Documented Interactions

Interaction with certain medications may lead to changes in Angistad's effectiveness:

• The blood pressure-raising effect of dihydroergotamine may be increased when taken simultaneously with Angistad.
• A weakening of the effect of Angistad cannot be excluded when used with Non-steroidal Anti-rheumatic Drugs (NSAIDs).

Angistad is a prodrug that undergoes metabolism to release Nitric Oxide (NO), a gaseous signaling molecule. NO functions as an indirect activator by binding to and stimulating the enzyme soluble Guanylyl Cyclase (sGC), primarily within vascular smooth muscle cells. This interaction sharply increases the intracellular concentration of the second messenger cyclic Guanosine Monophosphate (cGMP). Elevated cGMP activates a cascade that ultimately leads to smooth muscle relaxation and wide-ranging vasodilation.

This vasodilation selectively increases the capacity of the venous system, causing a substantial reduction in venous return to the heart (reduced preload). Simultaneous dilation of arteries reduces resistance to blood flow (reduced afterload). The resulting decrease in cardiac volume and pressure loads decreases the heart's overall workload and oxygen consumption. Additionally, the mechanism induces coronary artery dilation, altering the ratio of oxygen supply to oxygen demand in the heart muscle. Continuous exposure can lead to depletion of necessary sulfhydryl groups, causing nitrate tolerance, a diminished physiological responsiveness that necessitates a drug-free interval for recovery.

How to Use Angistad

Angistad, which contains Isosorbide Mononitrate, is administered through the oral route as tablets. Its usage protocol is strictly defined, emphasizing a specific time schedule to manage tolerance development, a key consideration for long-term use.

---

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral (by mouth)
Dosage Forms	Immediate-Release (IR) and Extended-Release (ER) Tablets

---

Dosing and Frequency

The frequency of use is precisely structured to incorporate a required daily nitrate-free interval. For Immediate-Release (IR) tablets, the typical maintenance dose is 20 mg twice daily, with the doses required to be separated by approximately seven hours (e.g., 8 AM and 3 PM). This asymmetric timing is necessary to create the nitrate-free period.

Extended-Release (ER) tablets are typically used once daily in the morning. The starting dose for this form is commonly 30 mg or 60 mg, and the dose may be increased to a maximum dose of up to 240 mg once daily.

---

Procedural Conditions

Form Integrity: The Extended-Release tablets must be swallowed whole with fluid and are not to be crushed, chewed, or split. Altering the tablet structure compromises its sustained-release profile.

Population Caution: For older adults, standard guidelines specify initiating therapy at the low end of the dosing range. If a dose is missed, it should be omitted, and the user should continue with the next scheduled dose; doubling the dose is not permitted.

Research evidence / Overview of studies for Angistad

Evidence for Use in Chronic Stable Angina Pectoris

The main research for Angistad (Isosorbide Mononitrate) was conducted in Chronic Stable Angina Pectoris, utilizing Randomized Controlled Trials (RCTs) and systematic reviews in adult populations, including older patients. Studies focused on measuring outcomes related to physical discomfort, exploring endpoints such as angina attack frequency and the need for rescue short-acting nitrate medication. Research monitored functional exercise capacity during stress testing. Findings describe patterns where a lower number of weekly angina events was measured and lower consumption of short-acting nitrate medication was monitored compared to a placebo. However, long-term effects on overall patient-reported quality of life (QoL) are not fully established, and follow-up durations were limited.

---

Evidence for Angistad in Other Cardiac Conditions

Research on Chronic Heart Failure (CHF)

Angistad was evaluated in randomized, double-blind, placebo-controlled trials for patients with Chronic Congestive Heart Failure (CHF). These studies focused on outcomes reflecting daily functioning or activity level (exercise capacity) and neurohormonal markers. The evidence is limited and findings were mixed. Studies reported that the change in the primary functional endpoint in the overall patient cohorts was observed to be not consistently significant when compared to placebo. The overall functional benefit in chronic heart failure is not established by the existing research.

Emerging Data Post-Coronary Artery Bypass Grafting (CABG)

Studies explored the use of Angistad in adults post-bypass surgery involving a radial artery graft, measuring the rate of Radial Artery (RA) graft failure and Major Adverse Cardiovascular Events (MACE). These are primarily pilot Randomized Controlled Trials and data are still emerging.

---

Study Limitations and Research Gaps

Research highlights areas of uncertainty. A key challenge studied is nitrate tolerance (diminished pharmacological response over time), which was studied for long-term use. For special patient groups, such as children, the data remain insufficient for a full characterization. The results apply only to the populations studied, and the evidence quality varies across studies, particularly for non-angina uses.

Key Studies & References

1. Isosorbide Mononitrate Extended-Release Tablets, USP Rx only (DailyMed/FDA Label)
2. Nitrates in Congestive Heart Failure (NICE) Study: Effect of isosorbide-5-mononitrate on exercise performance

Common questions about Angistad (FAQ)

---

Q: Can I take Lisinopril if I'm pregnant or breastfeeding?

A: Official regulatory documents carry a strong warning that discontinuation of Angistad (Lisinopril) is necessary as soon as pregnancy is detected. This is because medicines that directly act on the renin-angiotensin system (like this one) are associated with risk of injury or death to the developing fetus. Regarding breastfeeding, the product information states that it is generally recommended not to breastfeed while using this medication.

---

Q: Can Lisinopril cause hair loss?

A: Based on official regulatory documents, hair loss, which is medically known as alopecia, has been reported as an adverse reaction. This effect was observed in clinical studies involving patients treated with Angistad (Lisinopril).

---

Q: Does Lisinopril make your skin more sensitive to the sun?

A: The official product information for Angistad (Lisinopril) as a single ingredient does not specifically list sun sensitivity. However, for combination products that include a diuretic like Hydrochlorothiazide, the regulatory label indicates that there is a need to protect skin from the sun and avoid sunlamps, as the diuretic component has been associated with an increased risk of certain skin cancers.

How to Store and Dispose of Angistad

Angistad (Isosorbide Mononitrate) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The medication requires specific handling to maintain its stability, which includes keeping it in a tightly closed container and protecting it from excessive moisture, direct light, and heat. It is strictly mandated to keep this medication from freezing.

For household safety, the product must be stored in a secure location and placed out of the reach of children.

To dispose of unused or expired Angistad, do not keep outdated product. Patients are instructed to ask their healthcare professional or pharmacist for guidance on the proper disposal procedure to ensure local regulations are followed.